Although a variety of ATP-competitive FGFR1 inhibitors with therapeutic prospects for lung cancer have been identified, most of them failed in pre-clinical or clinical studies because of their low efficacy or high toxicity. The gene discussed is FGFR1; the disease is lung cancer.